# Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

> **NCT03779191** · PHASE2 · COMPLETED · sponsor: **Instituto Nacional de Cancerologia de Mexico** · enrollment: 41 (actual)

## Conditions studied

- ALK Gene Rearrangement Positive
- Non-Squamous Non-Small Cell Neoplasm of Lung

## Interventions

- **DRUG:** Alectinib
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03779191
- **Lead sponsor:** Instituto Nacional de Cancerologia de Mexico
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-08
- **Primary completion:** 2022-08-01
- **Final completion:** 2022-10-30
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03779191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03779191, "Alectinib in Combination With Bevacizumab in ALK Positive NSCLC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03779191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*